Last update 26 Jan 2025

KSD-101

Overview

Basic Info

Drug Type
Therapeutic vaccine, Dendritic cell vaccine
Synonyms-
Target
EBV Protein
Mechanism
EBV Protein inhibitors
Therapeutic Areas
NeoplasmsHemic and Lymphatic DiseasesMouth and Tooth Diseases+ [2]
Active Indication
Hematologic NeoplasmsEpstein-Barr virus associated Nasopharyngeal CarcinomaNasopharyngeal Carcinoma
Inactive Indication-
Originator Organization
Zhongshan Hengsai Biological Technology Co., Ltd.Zhongshan Hengsai Biological Technology Co., Ltd.
Active Organization
Zhongshan Hengsai Biological Technology Co., Ltd.Zhongshan Hengsai Biological Technology Co., Ltd.Shanghai Tongji Hospital
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with KSD-101
NCT06752473
/ Not yet recruitingEarly Phase 1
KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial
NCT06370026
/ Not yet recruitingEarly Phase 1IIT
KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial
NCT06097793
/ RecruitingEarly Phase 1
KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial
100 Clinical Results associated with KSD-101
Login to view more data
100 Translational Medicine associated with KSD-101
Login to view more data
100 Patents (Medical) associated with KSD-101
Login to view more data
100 Deals associated with KSD-101
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Epstein-Barr virus associated Nasopharyngeal CarcinomaPhase 1
CN
Zhongshan Hengsai Biological Technology Co., Ltd.Zhongshan Hengsai Biological Technology Co., Ltd.
04 Dec 2023
Nasopharyngeal CarcinomaPhase 1
CN
Zhongshan Hengsai Biological Technology Co., Ltd.Zhongshan Hengsai Biological Technology Co., Ltd.
04 Dec 2023
Hematologic NeoplasmsPhase 1
CN
Shanghai Tongji Hospital
16 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ASH2023
Phase 1
Hematologic Neoplasms
9
yseuuolcen(hfqnupapkf) = kghzaukxsj abrgpijtnm (wunqfhcfsg )
-
11 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free